drugset / Trial / NCT06461546
Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, pilot, prospective, unicentric trial, to evaluate Imlifidase could improve the transplantability of the highly sensitized patients with good outcomes respect to survival and functionality of the graft.
Timeline
- Start
- 2024-10-22
- Primary completion
- 2026-12
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imlifidase | Protein / enzyme biologic | 0.25 mg/kg | — |
Indications
No indication recorded.